Driving deep collaboration between a global pharmaceutical giant and a clinical research organisation
A failing high-stake partnership had jeopardized the delivery of a significant clinical study
For 18 months, a high profile global study for a critical new product was struggling to meet timelines and essential patient recruitment for the launch was running 60% behind target
Being delivered in partnership with a Clinical Research Organisation, the stakes were high for both parties; potentially jeopardising long term strategic ambitions at a senior level. Relationships had broken down within the team and frustration was high, threatening the study at large. Belief in the study was at an all-time low of; “this is impossible to recover”
Both organisations had taken steps to get the study back on track, but because of significant doubt, blame and lack of trust, people on both sides resigned to the project not being delivered.
1. Pre-work dialogue with individual stakeholders involved:
2. Strategic partnering programme (workshop based)
3. Coaching of key people in study team between meetings to resolve live setbacks in the day to day study operations.
4. Both companies appointed alliance managers who held them jointly accountable for their commitments with a direct line to senior management.
"Focusing the teams on what needed to be done; by whom and when and having removed the ‘toxic’ atmosphere of blame, enabled both teams to rise to the challenge. It became significant, high profile and delivered results which had been considered unpredictable. The learning & the behaviour has remained with the team long after the intervention - as powerfully as when it was first delivered" Pharmaceutical Sponsor
"The experiences and learnings both our teams gained during this collaboration gave them the confidence to tackle challenges they had avoided in the past – and will make a huge difference to their individual careers and the performance of their respective organisations" SVP Managing Director Global, CRO
"The accomplishments of the joint sponsor/CRO study team in achieving the seemingly unreachable 30,000 patient enrolment milestone cannot be underestimated. The data collected from this huge number of patients allows us the opportunity to understand real world safety and effectiveness in a way not previously possible and to directly translatable into clinical practice to optimize patient outcomes. I was cautioned against joining this team because of the previous difficulties but it is now a privilege to be involved in such a study." Pharmaceutical Director Global Medical Affair
"I didn’t believe at the outset that this was possible, the transformation in the way we work is amazing" Global Trial Leader in Pharmaceutical